OLIPOP Raises $200M to Expand Prebiotic Soda Market Leadership
OLIPOP didn’t get acquired. It got selective. After M&A conversations cooled off without a deal, OLIPOP is back in the market raising $200M, building on a $50M Series C in February 2025 that locked in a $1.85B valuation. That’s not a pivot, that’s posture. When a company can walk away from a sale and still draw a crowd, you’re not watching a process unfold. You’re watching leverage tighten its grip.
Ben Goodwin (CEO) and David Lester (Co-Founder) have been playing the long game since before gut health was a grocery store headline. From the Obi chapter to OLIPOP’s current shelf dominance, this wasn’t about catching a trend. It was about engineering one. Prebiotic soda sounds like a niche until it starts moving at scale, then suddenly the incumbents look like they missed a meeting they were supposed to lead.
The machine behind it is just as sharp. Melvin Landis (President) brings decades of beverage muscle, the kind that understands distribution isn’t logistics, it’s strategy. Tracy Hart (CFO) runs the numbers with operator discipline, where growth isn’t a headline, it’s a system that holds under pressure. And on the cap table side, names like Jared Stein of Monogram Capital Partners and J.P. Morgan Growth Equity Partners don’t show up for novelty. They show up when the math and the momentum agree.
Morgan Stanley advising this secondary tells you exactly what kind of room this conversation is happening in. This isn’t survival capital. This is liquidity with intent. Early believers get optionality, new entrants get proximity, and OLIPOP keeps control of the tempo. Not many brands get to dictate terms after passing on an exit. Fewer make it look routine.
Meanwhile, the product keeps doing what the pitch promised. High fiber, low sugar, plant-based, and somehow still hitting that nostalgia nerve without tasting like compromise. Distributed across 50,000+ locations and profitable in 2024, OLIPOP didn’t just enter the soda aisle, it started rearranging it. Quietly at first, then all at once.
That’s the part most people miss. This isn’t about soda. It’s about behavior. Consumers are recalibrating what “better” feels like, and OLIPOP is meeting them right at that intersection of memory and metabolism. Familiar taste, different outcome. That’s a hard equation to solve, and an even harder one to scale.
Now there’s $200M on the table again, no confirmed lead, just interest circling a company that didn’t need to sell to prove it could. That kind of signal travels. It moves through boardrooms, investor calls, late-night models that suddenly need to be adjusted. Because when a brand like OLIPOP decides to stay independent, it doesn’t just keep its equity. It keeps its narrative. And right now, that narrative is compounding.
